|Bid||91.09 x 100|
|Ask||95.50 x 200|
|Day's Range||92.91 - 94.49|
|52 Week Range||92.52 - 153.15|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 12, 2018 - Feb 16, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||143.00|
NEW YORK, NY / ACCESSWIRE / January 12, 2017 / U.S. markets rallied sharply Thursday as investor focus has now shifted to the upcoming earnings season. The Dow Jones Industrial Average jumped 0.81 percent ...
Incyte (INCY) slid to the bottom of the S&P 500 on Thursday, as worries from news earlier in the week mounted. Incyte lost $3.56, or 3.7%, to $93.06, while the S&P 500 climbed 19.33 points, or 0.70%, to 2767.56. There wasn't any new news on Incyte today, however the shares, which closed near their 52-week low, were dogged by worries from earlier this week, when Celgene (CELG) purchased Impact Biomedicines, which is working on a rival treatment to Incyte's blood cancer drug Jakafi. Leerink's Michael Schmidt reiterated an Outperform rating on the stock yesterday, when it began to drop following strength early in the week.
As we discussed earlier, Incyte (INCY) reported a 41.6% rise in its revenue to $381.5 million in 3Q17. Further, Wall Street analysts expect a 26.7% rise in Incyte’s revenue to $413.8 million in 4Q17 and a 35.9% rise in its revenue to $1.5 billion for the entirety of 2017. Incyte’s stock price has fallen nearly 4.3% over the last 12 months and nearly 3.9% year-to-date in 2018.
As we discussed earlier, Incyte (INCY) reported revenue of $381.5 million in 3Q17, a 41.6% rise over its revenue of $269.5 million in 3Q16. This revenue growth was driven by increased demand for the drug Jakafi. The above graph shows a revenue breakup for Incyte over the last few quarters.
Incyte Corporation and Syros Pharmaceuticals, Inc. announced today that the companies have entered into a target discovery, research collaboration and option agreement.
Puma, Clovis and Incyte could outperform other midcap biotechs this year, an analyst says, listing the trio as his favorites for 2018.
Leading Incyte Corporation (NASDAQ:INCY) as the CEO, Hervé Hoppenot took the company to a valuation of $21.29B. Understanding how CEOs are incentivised to run and grow their company is anRead More...
Bristol-Myers Squibb, Incyte, and Nektar Therapeutics could provide the biggest fireworks next year on the immunotherapy scene.
Zacks.com featured highlights: Incyte, AMC Entertainment, Mercadolibre, PTC and Clean Harbors
Incyte Corporation announced today that it will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 1:30 pm in San Francisco.
With tax reform on the horizon, the biotech sector is expected to witness a surge in M&A deals. Here is a look at Juno (JUNO) and two other biotech stocks that could be on the acquisition radar.